Medicine
Priftin 150 mg tablet
Priftin 150 mg tablet is a prescription medicine containing Rifapentine for oral use, marketed by Sanofi-Aventis, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions permitted 15–30°C (59–86°F). Protect from…
Key facts
- Active ingredient (INN)
- Rifapentine
- Brand
- Priftin
- Strength
- 150 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 3 blister pack
- Marketing authorisation holder
- Sanofi-Aventis
- Manufacturer
- Sanofi-Aventis
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted 15–30°C (59–86°F). Protect from excessive heat and humidity.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J04AB05 Rifapentine
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 February 2017
- Identifiers
- RxCUI 242671, 261101DailyMed set ID 3a64fb70-b85e-43d9-8bcd-7e893f568ae1NDC 0088-2102Application NDA021024
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 3 blister pack in 1 carton / 8 tablet, film coated in 1 blister pack | 0088-2102-24 | sanofi-aventis | 8 February 2017 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 22 June 1998 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Rifapentine 150 mg tablet.
Clinical summary
Rifapentine is a rifamycin antimycobacterial indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis, among other approved uses. MedsAcross supplies Rifapentine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RifapentineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Priftin prescribing information (sanofi-aventis) · U.S. National Library of Medicine, DailyMed
Need Priftin 150 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.